Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis

Published:2016-12 Issue:12 Volume:107 Page:1837-1842
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Goto Koichi¹,Endo Masahiro²,Kusumoto Masahiko³,Yamamoto Nobuyuki⁴,Ohe Yuichiro⁵,Shimizu Ayaka⁶,Fukuoka Masahiro⁷

Affiliation:

1. Department of Thoracic Oncology; National Cancer Center Hospital East; Chiba Japan

2. Department of Diagnostic Radiology; Shizuoka Cancer Center; Shizuoka Japan

3. Department of Diagnostic Radiology; National Cancer Center Hospital East; Chiba Japan

4. 3 Department of Internal Medicine; Wakayama Medical University; Wakayama Japan

5. Division of Thoracic Oncology; National Cancer Center Hospital; Tokyo Japan

6. Chugai Pharmaceutical Co., Ltd; Tokyo Japan

7. Cancer Center; Izumi Municipal Hospital; Osaka Japan

Funder

Chugai Pharmaceutical Co. Ltd

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13096/fullpdf

Reference15 articles.

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

2. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan;Ohe;Ann Oncol,2007

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Randomised phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small cell lung cancer;Niho;Lung Cancer,2012

5. Randomised phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer;Johnson;J Clin Oncol,2004

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High risk and low incidence diseases: Massive hemoptysis;The American Journal of Emergency Medicine;2024-11

2. Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database;Frontiers in Pharmacology;2024-06-24

3. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy;Radiation Oncology;2024-05-30

4. Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy;Journal of Translational Medicine;2023-06-07

5. IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment;Journal of Thoracic Disease;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3